Evaxion Biotech A/S
NASDAQ:EVAX
Income Statement
Earnings Waterfall
Evaxion Biotech A/S
Income Statement
Evaxion Biotech A/S
| Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+70%
|
0
+124%
|
3
+1 085%
|
3
+1%
|
3
-2%
|
3
-4%
|
8
+141%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(10)
|
(17)
|
(23)
|
(26)
|
(27)
|
(26)
|
(26)
|
(25)
|
(25)
|
(25)
|
(24)
|
(22)
|
(20)
|
(19)
|
(18)
|
(18)
|
(18)
|
(17)
|
(17)
|
|
| Selling, General & Administrative |
(3)
|
(5)
|
(6)
|
(6)
|
(7)
|
(7)
|
(7)
|
(8)
|
(9)
|
(10)
|
(11)
|
(10)
|
(9)
|
(9)
|
(8)
|
(7)
|
(8)
|
(8)
|
(7)
|
|
| Research & Development |
(7)
|
(12)
|
(16)
|
(20)
|
(20)
|
(19)
|
(19)
|
(17)
|
(16)
|
(15)
|
(14)
|
(12)
|
(11)
|
(11)
|
(11)
|
(10)
|
(10)
|
(9)
|
(10)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
|
| Operating Income |
(10)
N/A
|
(17)
-72%
|
(23)
-35%
|
(26)
-14%
|
(27)
-5%
|
(26)
+3%
|
(26)
-1%
|
(25)
+5%
|
(25)
+0%
|
(25)
+2%
|
(24)
+1%
|
(22)
+9%
|
(20)
+9%
|
(19)
+5%
|
(15)
+21%
|
(15)
+2%
|
(14)
+4%
|
(14)
+2%
|
(9)
+34%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
1
|
0
|
0
|
1
|
1
|
3
|
3
|
1
|
1
|
(1)
|
(1)
|
(1)
|
5
|
3
|
3
|
3
|
0
|
1
|
3
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(9)
N/A
|
(17)
-81%
|
(22)
-34%
|
(25)
-10%
|
(26)
-6%
|
(24)
+10%
|
(24)
-1%
|
(24)
+0%
|
(24)
-2%
|
(25)
-4%
|
(25)
+0%
|
(23)
+9%
|
(16)
+32%
|
(16)
-3%
|
(12)
+24%
|
(11)
+7%
|
(14)
-24%
|
(13)
+10%
|
(6)
+50%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
1
|
2
|
2
|
0
|
0
|
(0)
|
(1)
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Income from Continuing Operations |
(8)
|
(15)
|
(20)
|
(25)
|
(26)
|
(24)
|
(25)
|
(23)
|
(24)
|
(25)
|
(24)
|
(22)
|
(15)
|
(15)
|
(11)
|
(11)
|
(13)
|
(12)
|
(5)
|
|
| Net Income (Common) |
(8)
N/A
|
(15)
-82%
|
(20)
-35%
|
(25)
-20%
|
(26)
-7%
|
(24)
+8%
|
(25)
-2%
|
(23)
+6%
|
(24)
-2%
|
(25)
-4%
|
(24)
+0%
|
(22)
+10%
|
(15)
+34%
|
(15)
-4%
|
(11)
+25%
|
(11)
+8%
|
(13)
-26%
|
(12)
+10%
|
(5)
+55%
|
|
| EPS (Diluted) |
-23.48
N/A
|
-40.06
-71%
|
-52.52
-31%
|
-62.92
-20%
|
-56.61
+10%
|
-50.71
+10%
|
-51.75
-2%
|
-49
+5%
|
-45.8
+7%
|
-45.33
+1%
|
-44.24
+2%
|
-40.46
+9%
|
-1.57
+96%
|
-1.41
+10%
|
-1.03
+27%
|
-0.98
+5%
|
-0.24
+76%
|
-0.03
+88%
|
-0.01
+67%
|
|